Pharmacoeconomic analysis of exemestane versus tamoxifen as adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer

被引：0
|
作者：
Gil, JM
Lluch, A
González, P
Del Castillo, A
Canorea, F
Rubio-Terrés, C
机构：
[1] Inst Catala Oncol, Barcelona, Spain
[2] Hosp Clin Univ Valencia, Valencia, Spain
[3] Pfizer, Madrid, Spain
[4] HERO Consulting, Madrid, Spain
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67253-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A37 / A38
页数：2
相关论文
共 50 条
  • [1] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    [J]. Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
  • [2] Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer
    Hillner, BE
    [J]. CANCER, 2004, 101 (06) : 1311 - 1322
  • [3] Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer
    Dignam, JJ
    Wieand, K
    Johnson, KA
    Fisher, B
    Xu, L
    Mamounas, EP
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) : 1467 - 1476
  • [4] The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer
    Fowble, B
    Fein, DA
    Hanlon, AL
    Eisenberg, BL
    Hoffman, JP
    Sigurdson, ER
    Daly, MB
    Goldstein, LJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (04): : 669 - 677
  • [5] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jon
    Sofrygin, Oleg
    Thomas, Simu K.
    Papo, Natalie L.
    Barghout, Victoria
    [J]. CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
  • [6] Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
    Criscitiello, Carmen
    Fumagalli, Debora
    Saini, Kamal S.
    Loi, Sherene
    [J]. ONCOTARGETS AND THERAPY, 2011, 4 : 1 - 11
  • [7] Updates on Adjuvant Therapy for Early Stage Hormone Receptor-Positive Breast Cancer
    Cavalcante, Ludimila L.
    Santa-Maria, Cesar A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (12) : 18 - 23
  • [8] Suboptimal adherence to adjuvant endocrine therapy (ET) in Brazilian women with early-stage estrogen receptor-positive (ER plus ) breast cancer
    Assad-Suzuki, Daniele
    Resende, Heloisa
    Santos, Danielle
    Moura, Fernanda
    Oliveira, Sulene
    Shimada, Andrea
    Galvao, Anna Luiza
    Souza, Bruno
    Castro, Amanda
    Andrade, Monalisa
    Beckedorff, Yuri
    Magalhaes, Maria Cristina
    Souza, Cristiano
    Paiva, Carlos
    Pereira, Daniela
    Rodrigues, Angelica
    Rosa, Daniela
    Barroso-Sousa, Romualdo
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [9] Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Nils Wilking
    Stig Holmberg
    Linus Jönsson
    [J]. Breast Cancer Research and Treatment, 2007, 102 : 289 - 299
  • [10] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Binghe Xu
    Huiping Li
    Zefei Jiang
    Lin Gu
    Jinhai Tang
    Hui Xie
    Yueyin Pan
    Yunjiang Liu
    Shude Cui
    Xiaojia Wang
    Li Cai
    Yiqiong Zhang
    Huadong Zhao
    Zhimin Shao
    [J]. Chinese Journal of Cancer Research, 2022, 34 (06) : 592 - 601
12345